Kazia Therapeutics Limited
KZIA · NASDAQ
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | – | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | – | $0 | $0 | $0 |
| Revenue | – | $0 | $0 | $0 |
| % Growth | – | -99.1% | 49,619,800% | – |
| Gross Profit | – | $0 | $0 | $0 |
| % Margin | – | 100% | 100% | 100% |
| EBITDA | – | -$0 | -$0 | -$0 |
| % Margin | – | -37,836.1% | -751.5% | -158,973,960% |
| Net Income | – | -$0 | -$0 | -$0 |
| % Margin | – | -46,899.1% | -723.7% | -176,470,260% |
| EPS Diluted | – | -6.15 | -31.2 | -18.4 |
| % Growth | – | 80.3% | -69.6% | – |
| Operating Cash Flow | – | -$0 | -$0 | -$0 |
| Capital Expenditures | – | $0 | $0 | $0 |
| Free Cash Flow | – | -$0 | -$0 | -$0 |